FDA puts three CARs­gen CAR-T ther­a­pies on clin­i­cal hold, in­clud­ing Mod­er­na-part­nered pro­gram

Ques­tions re­lat­ed with chem­istry, man­u­fac­tur­ing and con­trols have trig­gered clin­i­cal holds for three of CARs­gen Ther­a­peu­tics’ CAR-T ther­a­pies, the biotech

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER